Digoxin Dosing for Paroxysmal Atrial Fibrillation

Initial Dosing Strategy

The European Society of Cardiology recommends an oral maintenance dose of digoxin of 0.0625-0.25 mg daily for paroxysmal atrial fibrillation, with lower doses for patients over 70 years, those with impaired renal function, or low lean body mass 1, 2, 3
For most adults with normal renal function, the initial dose of digoxin is 0.125-0.25 mg daily, according to the European Heart Journal 1, 3
For patients over 70 years, with impaired renal function, or low lean body mass, the American Heart Association suggests using lower doses of digoxin, such as 0.125 mg daily or 0.0625 mg daily 4, 3

The American College of Cardiology recommends maintaining a target serum digoxin concentration between 0.5-0.9 ng/mL 4, 3
Serum digoxin levels above 1.0 ng/mL have not shown superior outcomes and may increase mortality risk, as stated by the American Heart Association 4, 3

Beta-blockers are usually more effective when added to digoxin for rate control, particularly during exercise, according to the American College of Cardiology 4

The European Society of Cardiology advises reducing digoxin dose when used with medications that increase digoxin levels, such as amiodarone, verapamil, quinidine, and clarithromycin 4, 3
Digoxin is contraindicated in patients with significant sinus or AV block without a permanent pacemaker, as stated by the American Heart Association 4, 3

For rate control, beta-blockers and calcium channel blockers are generally more effective first-line options than digoxin, according to the European Heart Journal 1, 2

Gastrointestinal symptoms, such as anorexia, nausea, and vomiting, are common side effects of digoxin, as reported by the American College of Cardiology 4, 3
Neurological complaints, including visual disturbances, confusion, and disorientation, can occur with digoxin use, as stated by the American Heart Association 4, 3
Cardiac arrhythmias, such as ectopic beats and heart block, are potential side effects of digoxin, according to the European Society of Cardiology 4, 3